Scedosporium apiospermum soft tissue infection successfully treated with voriconazole:: Potential pitfalls in the transition from intravenous to oral therapy

被引：31

作者：

Schaenman, JM

DiGiulio, DB

Mirels, LF

McClenny, NM

Berry, GJ

Fothergill, AW

Rinaldi, MG

Montoya, JG

机构：

[1] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA

[2] Stanford Univ, Sch Med, Div Infect Dis & Geog Med, Stanford, CA 94305 USA

[3] Stanford Univ, Sch Med, Clin Microbiol Lab, Stanford, CA 94305 USA

[4] Stanford Univ, Sch Med, Dept Pathol, Stanford, CA 94305 USA

[5] Santa Clara Valley Med Ctr, Dept Med, Div Infect Dis, San Jose, CA 95128 USA

[6] Calif Inst Med Res, San Jose, CA 95128 USA

[7] Palo Alto Med Fdn, Res Inst, Dept Immunol & Infect Dis, Palo Alto, CA 94301 USA

[8] Univ Texas, Hlth Sci Ctr, Dept Pathol, San Antonio, TX USA

来源：

JOURNAL OF CLINICAL MICROBIOLOGY | 2005年 / 43卷 / 02期

关键词：

D O I：

10.1128/JCM.43.2.973-977.2005

中图分类号：

Q93 [微生物学];

学科分类号：

071005 ; 100705 ;

摘要：

An immunocompromised patient with an invasive soft tissue infection due to Scedosporium apiospermum was successfully treated with voriconazole and surgical debridement. After transition from intravenous to oral therapy, successive adjustments of the oral dose were required to achieve complete resolution. For soft tissue infections due to molds characterized by thin, septate hyphae branching at acute angles, voriconazole should be considered a first-line antifungal agent. The potential usefulness of plasma voriconazole levels for guiding optimal therapy should be investigated.

引用

收藏

页码：973 / 977

页数：5

相关论文

共 47 条

[1] Salvage therapy with voriconazole for invasive fungal infections in patients failing or intolerant to standard antifungal therapy [J].

Baden, LR ;

Katz, JT ;

Fishman, JA ;

Koziol, C ;

DelVecchio, A ;

Doran, M ;

Rubin, RH .

TRANSPLANTATION, 2003, 76 (11) :1632-1637

[2] Scedosporium infection in immunocompromised patients:: Successful use of liposomal amphotericin B and itraconazole [J].

Barbaric, D ;

Shaw, PJ .

MEDICAL AND PEDIATRIC ONCOLOGY, 2001, 37 (02) :122-125

[3] Two cases of subcutaneous Scedosporium apiospermum infection treated with voriconazole [J].

Bosma, F ;

Voss, A ;

van Hamersvelt, HW ;

de Sévaux, RGL ;

Biert, J ;

Kullberg, BJ ;

Melchers, WGJ ;

Verweij, PE .

CLINICAL MICROBIOLOGY AND INFECTION, 2003, 9 (07) :750-753

[4] Cutaneous Scedosporium apiospermum infection in an immunocompromised patient [J].

Bower, CPR ;

Oxley, JD ;

Campbell, CK ;

Archer, CB .

JOURNAL OF CLINICAL PATHOLOGY, 1999, 52 (11) :846-848

[5] Lymphocutaneous syndrome due to Scedosporium apiospermum [J].

Canet, JJ ;

Pagerols, X ;

Sánchez, C ;

Vives, P ;

Garau, J .

CLINICAL MICROBIOLOGY AND INFECTION, 2001, 7 (11) :648-650

[6] Efficacy of voriconazole in treatment of systemic scedosporiosis in neutropenic mice [J].

Capilla, J ;

Serena, C ;

Pastor, FJ ;

Ortoneda, M ;

Guarro, J .

ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (12) :3976-3978

[7] Cutaneous infection due to Scedosporium apiospermum in an immunosuppressed patient [J].

Chaveiro, MA ;

Vieira, R ;

Cardoso, J ;

Afonso, A .

JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2003, 17 (01) :47-49

[8] Comparative in-vitro activity of voriconazole (UK-109,496) and six other antifungal agents against clinical isolates of Scedosporium prolificans and Scedosporium apiospermum [J].

Cuenca-Estrella, M ;

Ruiz-Díez, B ;

Martínez-Suárez, JV ;

Monzón, A ;

Rodríguez-Tudela, JL .

JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 1999, 43 (01) :149-151

[9] Amphotericin B responsive Scedosporium apiospermum infection in a patient with acute myeloid leukaemia [J].

Cunningham, R ;

Mitchell, DC .

JOURNAL OF CLINICAL PATHOLOGY, 1996, 49 (01) :93-94

[10] Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis [J].

Denning, DW ;

Ribaud, P ;

Milpied, N ;

Caillot, D ;

Herbrecht, R ;

Thiel, E ;

Haas, A ;

Ruhnke, M ;

Lode, H .

CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :563-571

← 1 2 3 4 5 →